ALDEYRA THERAPEUT. WKN: A111X8 ISIN: US01438T1060 Kürzel: ALDX Forum: Aktien Thema: Hauptdiskussion

Shortseller Attacke Man versucht den Kurs zu drücken und zu verunsichern.

Versteh ich jetzt auch nicht 🙄

Und warum fällt der Kurs soooo extrem? Verrückte Welt

Kaufen!!!!

Erfolgreiche Ergänzung Phase 2 Daten für Zulassung

https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-achievement-primary-endpoint

Nur noch wenige Tage \ Wochen und die Phase 3 Daten werden veröffentlicht - Kurs Explosion voraus - schätze 12,5 - 15 USD

Niva400 Leider kann ich in den Artikel nicht hinein schauen geht nicht auf. Kannst du in Übersetzen und reinstellen. Danke

Mind 12,5 USD Vielleicht 16 USD

Wie hoch soll der Kurs gehen bis Weihnachten?

Ergebnisse für Q4 bestätigt, Kursexplosion bis Weihnachten 🎄 🎄 🎄 :-)

Heute 14 Uhr wirds spannend

https://stocktwits.com/symbol/ALDX

Bin bei stocktwits, da ist mehr los! Heute Q3 Ergebnisse

Jemand mal wieder neue News ?

BREAKING: Excited to announce that the peer-reviewed journal Clinical Ophthalmology has published the results of a #clinicaltrial comparing the subjective eye drop experience of patients with #dryeyedisease over 1 hour after a single dose of two formulations of our RASP inhibitor, #reproxalap, versus lifitegrast. On the measures of eye drop comfort, both reproxalap formulations consistently scored higher than lifitegrast. Dry eye disease affects tens of millions of patients in the U.S. every year. Patients typically suffer from ocular discomfort, visual disturbance, tear film instability, increased tear osmolarity, conjunctival redness, and inflammation of the ocular surface that, in severe case, can lead to vision loss. Lifitegrast is one of only two drugs approved for the chronic treatment of dry eye disease, but due to common side effects, such as ocular irritation, blurred vision, and taste disturbance, approximately two-thirds of patients discontinue treatment after a median of just 1 month. Given the complex and chronic nature of dry eye disease, a therapy that results in greater patient adherence is critical. At Aldeyra, we’ve made it our mission to develop safe and effective treatments that improve the lives of patients with significant unmet medical needs. The results of this head-to-head trial demonstrate not only that reproxalap has broad statistically significant advantages over lifitegrast in assessments of the most common lifitegrast side effects. The trial also shows that reproxalap’s superior performance with regard to the most commonly reported side effects of lifitegrast may result in greater patient adherence and lower discontinuation rates. The paper, “A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease” is available online here: https://bit.ly/39yCzba